Notícias

Eli Lilly stock gains 14% in a month as strong Q1 results, obesity drug coverage expansion and promising retatrutide data fueled momentum.

TD Cowen expects around 59 million patients worldwide to be using GLP-1 therapies by the end of the decade, up sharply from its previous estimate of 46 million.

Novo Nordisk (CPSE:NOVO B) has signed a clinical supply agreement with Veru Inc. to provide Wegovy for a Phase 2b obesity trial in older adults. The PLATEAU study will test Wegovy alongside Veru’s enobosarm, a selective androgen receptor modulator, in combination therapy. Novo Nordisk retains no development rights to enobosarm but has secured a right of first negotiation for potential future collaborations with Veru. For investors tracking CPSE:NOVO B, this agreement comes as the share...

Veru will evaluate enobosarm alongside Novo Nordisk’s Wegovy in the Phase 2b PLATEAU trial in older adults with obesity.

Veru Inc. (NASDAQ:VERU) has entered into a clinical supply agreement with Novo Nordisk A/S (NYSE:NVO) to support its upcoming Phase 2b PLATEAU study, which will investigate a combination treatment for obesity in older adults.

Eli Lilly knows that its GLP-1 windfall comes with an end date, so it is acting now to prepare.

A share price rally pushed ASML's market cap to $668 billion on Wednesday, beating a European record set by Novo Nordisk in June 2024.

The Dutch chipmaker eclipses Novo Nordisk's 2024 peak as AI infrastructure demand drives a 130% rally.

Danske Bank lifts Denmark outlook again as Novo Nordisk demand supports export growth.

There is light at the end of the tunnel.

Novo Brings Oral Obesity Drug To UAE Patients

European stock markets closed lower Wednesday as the Stoxx Europe 600 fell 0.7%, Germany's DAX 40 sh

A launch in the United Arab Emirates comes as Novo works to recover ground in the weight loss drug market against rival Eli Lilly

Wells Fargo’s chief agriculture economist Dr. Michael Swanson told Bloomberg Businessweek on May 29 that GLP-1 weight-loss drugs (Ozempic, Wegovy, Mounjaro, Zepbound) will eventually match statins at roughly 90 million prescriptions, calling the trend “here to stay” because it’s prescribed, not faddish. So this is the next 90-million-customer industry, sitting in plain sight while everyone ... 5 Stocks Set to Cash in on The Next 90-Million Customer Industry. (It’s Not AI)

The pharmaceutical company's most promising drug candidate has some potential advantages over its rivals.

Novo Nordisk (NYSE:NVO) has introduced the tablet form of its blockbuster obesity treatment Wegovy in the United Arab Emirates, marking the second country worldwide to receive the oral version of the medication. The launch follows regulatory approval granted earlier this week by health authorities in the UAE and comes several months after the Danish pharmaceutical group debuted the product in the United States.

Novo Nordisk (CPSE:NOVO B) has launched the Wegovy pill in the UAE, the first country outside the U.S. to offer this oral obesity treatment. Regulators in the EU have issued positive opinions recommending approval of both the Wegovy pill and a higher dose injectable formulation. The company is expanding obesity care access through partnerships, including a collaboration with NOVI Health in Singapore. Novo Nordisk, through CPSE:NOVO B, is a major player in obesity and diabetes care, and...

The UAE launch marks the start of Novo's global rollout, with additional launches planned later this year.

Eli Lilly and Company just secured a big win as it looks to expand GLP-1 access, mending its partnership with top pharmacy benefit manager CVS Health.

An upcoming trial result could change how investors think about the weight-loss drug market.

We recently compiled a list of the 11 Most Undervalued Pharma Stocks to Invest In. Novo Nordisk A/S (NYSE:NVO) is one of the most undervalued stocks to invest in. TheFly reported on May 27 that NVO announced that it will present new clinical findings from its cardiometabolic portfolio at the 2026 Scientific Sessions of the American […]

PFE targets a catalyst-rich 2026 with pivotal obesity and oncology studies, key data readouts, and regulatory decisions across its pipeline.

Lilly shares soared more than 18% in May.

These 5 long-term growth stocks could benefit from AI, cybersecurity, GLP-1 drugs, and fintech trends over the next decade

Eli Lilly is working on a new GLP-1 drug, and early results suggest it could be a big winner.

CVS Caremark has granted preferred formulary status to both Novo Nordisk's Wegovy and Eli Lilly's Zepbound and Foundayo. This decision reverses Wegovy's prior commercial advantage within CVS Caremark's GLP-1 obesity drug coverage. The change affects access and competitive positioning for GLP-1 obesity therapies in CVS Caremark's network. Novo Nordisk, listed as CPSE:NOVO B, is a key player in GLP-1 based therapies, with Wegovy at the center of its obesity drug portfolio. CVS Caremark's move...

Lilly has split its stock in the past.

We just covered the Claude Stock Portfolio: Top 10 Stocks to Buy According to AI Chatbot. Eli Lilly and Company (NYSE:LLY) ranks #2 (see Claude Stock Portfolio: Top 5 Stocks to Buy According to AI Chatbot). Number of Hedge Funds: 137 Eli Lilly and Company (NYSE:LLY) is among the top stock picks of the Claude […]

Eli Lilly hits a record high after CVS expands coverage for Foundayo and Zepbound, boosting obesity drug access and raising the stakes in its rivalry with NVO.

CVS restores broader Zepbound coverage after price cuts, putting Wegovy and Zepbound on equal footing.